Cognition Therapeutics (CGTX) Research & Development (2020 - 2026)
Cognition Therapeutics (CGTX) reported Research & Development of $6.1 million for Q1 2026, down 43.26% year-over-year from $10.8 million in Q1 2025, and down 45.1% on a QoQ basis from $11.1 million in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Research & Development data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Research & Development fell 43.26% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.5 million (down 22.4% YoY) and the FY2025 annual result came in at $37.2 million, down 10.77% from the prior year.
- Research & Development fell to $6.1 million in Q1 2026 per CGTX's latest filing, from $11.1 million in the prior quarter.
- Across five years, Research & Development topped out at $11.7 million in Q3 2023 and bottomed at $3.8 million in Q3 2025.
- The 5-year median for Research & Development is $10.6 million (2024), against an average of $9.1 million.
- The widest annual swing landed in 2022, when Research & Development surged 124.98%; it then slumped 66.88% in 2025.
- Tracing CGTX's Research & Development over 5 years: stood at $8.3 million in 2022, then jumped by 40.3% to $11.6 million in 2023, then slipped by 29.71% to $8.2 million in 2024, then surged by 36.71% to $11.1 million in 2025, then plunged by 45.1% to $6.1 million in 2026.
- Per Business Quant, the three latest CGTX Research & Development figures stand at $6.1 million (Q1 2026), $11.1 million (Q4 2025), and $3.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | 6.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | 11.15 Mn |
| Sep 30, 2025 | 3.77 Mn |
| Jun 30, 2025 | 11.48 Mn |
| Mar 31, 2025 | 10.79 Mn |
| Dec 31, 2024 | 8.15 Mn |
| Sep 30, 2024 | 11.39 Mn |
| Jun 30, 2024 | 11.58 Mn |
| Mar 31, 2024 | 10.55 Mn |
| Dec 31, 2023 | 11.60 Mn |
| Sep 30, 2023 | 11.67 Mn |
| Jun 30, 2023 | 8.50 Mn |
| Mar 31, 2023 | 5.43 Mn |
| Sep 30, 2022 | 8.27 Mn |
| Mar 31, 2022 | 6.52 Mn |
| Sep 30, 2021 | 3.68 Mn |
| Sep 30, 2020 | 3.40 Mn |